{
    "clinical_study": {
        "@rank": "139531", 
        "arm_group": {
            "arm_group_label": "DS-3032", 
            "arm_group_type": "Experimental", 
            "description": "DS-3032b will be administered as an oral capsule.  It will be supplied in 5 mg, 20 mg, 80 mg, and 200 mg capsules individually packaged in desiccant-embedded aluminum blisters."
        }, 
        "brief_summary": {
            "textblock": "This will be a Phase 1, open-label study of DS-3032b to assess its safety and tolerability,\n      identify an maximum tolerated dose (MTD)/tentative recommended phase 2 dose (RP2D), and\n      assess its pharmacokinetic (PK)/ pharmacodynamic (PD) properties in subjects with advanced\n      solid tumors or lymphomas.\n\n      Approximately 5 US sites are planned for Part 1 (Dose Escalation).  Approximately 10 US\n      sites are planned for Part 2 (Dose Expansion)."
        }, 
        "brief_title": "A Phase 1 Multiple Ascending Dose Study of DS-3032b, an Oral Murine Double Minute 2 (MDM2) Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Advanced Solid Tumor", 
            "Lymphoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Has a histologically or cytologically documented advanced solid tumor or lymphoma\n             that has relapsed from or is refractory to standard treatment, or for which no\n             standard treatment is available. Subjects with melanoma who are ineligible to receive\n             or have declined ipilimumab treatment, or who are refractory or intolerant to\n             ipilimumab may enroll.\n\n          -  Man or woman >= 18 years old.\n\n          -  Has an Eastern Cooperative Oncology Group (ECOG) performance status 0-1.\n\n          -  Has adequate bone marrow function, defined as:\n\n        Platelet count >= 100 x 109/L Hemoglobin >= 9.0 g/dL Absolute neutrophil count >= 1.5 x\n        109/L.\n\n        - Has adequate renal function, defined as: Creatinine clearance >= 60 mL/min, as\n        calculated using the modified Cockcroft Gault equation, ([{140 - age in years} \u00d7 {actual\n        weight in kg}] divided by [{72 \u00d7 serum creatinine in mg/dL} multiply by 0.85 if female]),\n        OR creatinine =< 1.5 x ULN.\n\n        - Has adequate hepatic function, defined as: AST/ALT levels =< 3 x ULN (if liver\n        metastases are present, =< 5 x ULN) Bilirubin =< 1.5 x ULN.\n\n        - Has adequate blood clotting function, defined as: International normalized ratio (INR)\n        and activated partial thromboplastin time (aPTT) =< 1.5 x ULN.\n\n          -  Subject should be able to provide written informed consent, comply with protocol\n             visits and procedures, be able to take oral medication, and not have any active\n             infection or comorbidity that would interfere with therapy.\n\n          -  Subject (male and female) of childbearing/reproductive potential must agree to use\n             double-barrier contraceptive measures or avoid intercourse during the study and for\n             90 days after the last dose of study drug.\n\n          -  Subject must be fully informed about their illness and the investigational nature of\n             the study protocol (including foreseeable risks and possible side effects) and must\n             sign and date an IRB [Institutional Review Board]-approved Informed consent Form\n             [ICF] (including Health Insurance Portability and Accountability Act authorization,\n             if applicable) before performance of any study specific procedures or tests.\n\n          -  Is willing to provide and there is confirmed availability of pre-existing diagnostic\n             or resected tumor samples, such as paraffin-embedded sections.  Providing fresh tumor\n             biopsy is optional for subjects in Dose Escalation cohorts.\n\n          -  Is willing to undergo tumor genotyping for TP53 mutation, insertion, or deletion at\n             screening.  Confirmation of TP53 nonmutant status is encouraged, but not required\n             prior to DS-3032b dosing.\n\n          -  Is willing to provide additional archived samples for comprehensive genomic and/or\n             proteomic analyses if the subject has a partial response/complete response to\n             DS-3032b treatment.\n\n        Exclusion Criteria:\n\n          -  Has a tumor that contains a nonsynonymous mutation, insertion, or deletion in the\n             TP53 gene determined previously or at screening.\n\n          -  Has a history of primary central nervous system malignancy.\n\n          -  Has gastrointestinal conditions that could affect the absorption of DS-3032b in the\n             opinion of the Investigator.\n\n          -  Has an uncontrolled infection requiring intravenous antibiotics, antivirals, or\n             antifungals, known human immunodeficiency virus infection, or active hepatitis B or C\n             infection.\n\n          -  Has received an allogeneic bone marrow or allogeneic stem cell transplant.\n\n          -  Has a concomitant medical condition that would increase the risk of toxicity, in the\n             opinion of the Investigator or Sponsor.\n\n          -  Has clinically active brain metastases, defined as untreated and symptomatic, or\n             requiring therapy with steroids or anticonvulsants to control associated symptoms.\n             Subjects with treated brain metastases that are no longer symptomatic and who require\n             no treatment with steroids may be included in the study if they have recovered from\n             the acute toxic effect of radiotherapy.  A minimum of 4 weeks must have elapsed\n             between the end of whole brain radiotherapy and study enrollment (2 weeks for\n             stereotactic radiotherapy).\n\n          -  Has unresolved toxicities from previous anticancer therapy, defined as toxicities\n             (other than alopecia) not yet resolved to NCI-CTCAE v4, grade =< 1 or baseline.\n             Subjects with chronic grade 2 toxicities may be eligible per the discretion of the\n             Investigator and Sponsor (eg, grade 2 chemotherapy-induced neuropathy).\n\n          -  Had an autologous transplant within 3 months of starting study drug treatment.\n\n          -  Is receiving concomitant treatment with a strong inhibitor or inducer of CYP3A4/5.\n\n          -  Had systemic treatment with anticancer therapy, antibody-based therapy, retinoid\n             therapy, or hormonal therapy within 3 weeks before study drug treatment; or treatment\n             with nitrosoureas or mitomycin C within 6 weeks before study drug treatment; or\n             treatment with small-molecule targeted agents within 2 weeks before study drug\n             treatment.  Previous and concurrent use of hormone replacement therapy, the use of\n             gonadotropin releasing hormone modulators for prostate cancer, and the use of\n             somatostatin analogs for neuroendocrine tumors are permitted if such therapy has not\n             been changed within 8 weeks before study drug treatment.\n\n          -  Had therapeutic radiation therapy or major surgery within 4 weeks before study drug\n             treatment or palliative radiation therapy within 2 weeks before study drug treatment.\n\n          -  Participated in a therapeutic clinical study within 3 weeks before study drug\n             treatment, or current participation in other therapeutic investigational procedures.\n\n          -  Prolongation of corrected QT interval by Fridericia's method (QTcF) at rest, where\n             the mean QTcF interval is > 450 milliseconds (ms) for males and > 470 ms for females\n             based on triplicate ECG.\n\n          -  Pregnant or breastfeeding.\n\n          -  Substance abuse or medical, psychological, or social conditions that, in the opinion\n             of the Investigator, may interfere with the subject's participation in the clinical\n             study or evaluation of the clinical study results.\n\n          -  Prior treatment with an MDM2 inhibitor."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "21", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01877382", 
            "org_study_id": "DS3032-A-U101"
        }, 
        "intervention": {
            "arm_group_label": "DS-3032", 
            "description": "DS-3032b will be administered as an oral capsule.  It will be supplied in 5 mg, 20 mg, 80 mg, and 200 mg capsules individually packaged in desiccant-embedded aluminum blisters.", 
            "intervention_name": "DS-3032", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 24, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48201"
                    }, 
                    "name": "Karmanos Cancer Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }, 
                    "name": "Tennessee Oncology"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "UT MD Anderson Cancer Center"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1 Multiple Ascending Dose Study of DS-3032b, an Oral MDM2 Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas", 
        "overall_contact": {
            "email": "a.ruwe@medpace.com", 
            "last_name": "Andrew Ruwe, PhD", 
            "phone": "513-579-9911", 
            "phone_ext": "2353"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "To determine the maximum tolerated dose (MTD) or tentative recommended Phase 2 dose (RP2D) of DS-3032b in subjects with advanced solid tumors or lymphomas.", 
                "measure": "maximum tolerated dose", 
                "safety_issue": "No", 
                "time_frame": "28 days"
            }, 
            {
                "description": "To assess tumor response in subjects with melanoma using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 and in subjects with diffuse large B-cell lymphoma (DLBCL) using the revised International Working Group (IWG) criteria.", 
                "measure": "tumor response", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01877382"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To determine the plasma pharmacokinetics (PK) of DS-3032a (the free form of DS-3032b).", 
                "measure": "plasma pharmacokinetics", 
                "safety_issue": "No", 
                "time_frame": "28 days"
            }, 
            {
                "description": "To determine the pharmacodynamic (PDy) effect of DS-3032b on macrophage inhibitory cytokine-1 (MIC-1) levels in serum.", 
                "measure": "effect on macrophage inhibitory cytokine-1 levels", 
                "safety_issue": "No", 
                "time_frame": "day 28"
            }, 
            {
                "description": "To evaluate the relationship between tumor response to DS-3032b and predictive biomarkers (e.g. p53, p21, p14, p16, MDM2, MDM4) studied in archived tumor samples and pre treatment tumor biopsies.", 
                "measure": "determine relationship between tumor response and biomarker p53", 
                "safety_issue": "No", 
                "time_frame": "day 8"
            }, 
            {
                "description": "To determine the PK profile of DS-3032a at the MTD/tentative RP2D.", 
                "measure": "Determine PK profile of DS-3032a at the MTD/tentative RP2D", 
                "safety_issue": "No", 
                "time_frame": "day 28"
            }, 
            {
                "description": "To determine the PD effect of DS-3032b on MIC-1 levels in serum.", 
                "measure": "Determine the PD effect of DS-3032b on MIC-1 levels in serum", 
                "safety_issue": "No", 
                "time_frame": "day 28"
            }
        ], 
        "source": "Daiichi Sankyo Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Daiichi Sankyo Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}